BR112017014085A2 - processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo - Google Patents

processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo

Info

Publication number
BR112017014085A2
BR112017014085A2 BR112017014085A BR112017014085A BR112017014085A2 BR 112017014085 A2 BR112017014085 A2 BR 112017014085A2 BR 112017014085 A BR112017014085 A BR 112017014085A BR 112017014085 A BR112017014085 A BR 112017014085A BR 112017014085 A2 BR112017014085 A2 BR 112017014085A2
Authority
BR
Brazil
Prior art keywords
preparation
tenofovir alafenamide
alafenamide hemifumarate
premixture
processes
Prior art date
Application number
BR112017014085A
Other languages
English (en)
Inventor
Neelima Bhagavatula
Anjaneyaraju Indukuri
Ramakoteswara Rao Jetti
M Kiran
R Mastanrao
B A Ramireddy
Amit Singh
P Subbarayudu
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of BR112017014085A2 publication Critical patent/BR112017014085A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo a presente invenção se refere a uma forma amorfa de hemifumarato de tenofovir alafenamida e processo para a preparação da mesma. uma pré-mistura de hemifumarato de tenofovir alafenamida amorfo com excipientes farmaceuticamente aceitáveis e processo para a preparação da mesma também são revelados.
BR112017014085A 2015-01-03 2015-12-31 processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo BR112017014085A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN14MU2015 2015-01-03
PCT/IB2015/060068 WO2016108205A1 (en) 2015-01-03 2015-12-31 Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Publications (1)

Publication Number Publication Date
BR112017014085A2 true BR112017014085A2 (pt) 2018-01-09

Family

ID=55346146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014085A BR112017014085A2 (pt) 2015-01-03 2015-12-31 processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo

Country Status (7)

Country Link
US (2) US20170348334A1 (pt)
EP (1) EP3240793A1 (pt)
JP (1) JP2018502118A (pt)
AU (1) AU2015373104B2 (pt)
BR (1) BR112017014085A2 (pt)
WO (1) WO2016108205A1 (pt)
ZA (1) ZA201704667B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651212T3 (es) 2011-07-07 2018-01-25 Janssen Sciences Ireland Uc Formulaciones combinadas de darunavir
CN107663217B (zh) * 2016-07-28 2021-03-02 苏州朗科生物技术股份有限公司 替诺福韦艾拉酚胺结晶化合物及其制备方法
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
BR112020000842A2 (pt) * 2017-07-20 2020-07-21 Janssen Sciences Ireland Unlimited Company composições e métodos para tratamento do hiv
CN107865874A (zh) * 2017-10-23 2018-04-03 上海博悦生物科技有限公司 一种替诺福韦艾拉酚胺的药物组合物及其制备方法
CN110526942A (zh) * 2019-06-18 2019-12-03 株洲千金药业股份有限公司 一种无定型富马酸替诺福韦艾拉酚胺及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1291994C (zh) 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
UY34262A (es) * 2011-08-16 2013-04-05 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos
CN104105484A (zh) * 2012-02-03 2014-10-15 吉联亚科学公司 用于治疗病毒感染的包含替诺福韦艾拉酚胺半反丁烯二酸盐和可比西他的组合疗法

Also Published As

Publication number Publication date
AU2015373104B2 (en) 2020-07-09
ZA201704667B (en) 2018-08-29
US20200261479A1 (en) 2020-08-20
US20170348334A1 (en) 2017-12-07
JP2018502118A (ja) 2018-01-25
EP3240793A1 (en) 2017-11-08
WO2016108205A1 (en) 2016-07-07
AU2015373104A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
BR112017014085A2 (pt) processos para a preparação de hemifumarato de tenofovir alafenamida amorfo e uma pré-mistura do mesmo
IN2014CH00247A (pt)
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
BR112019003437A2 (pt) processo para a fabricação de uma forma de administração farmacêutica sólida
CR20150096A (es) Formulaciones de trans-clomifeno y usos de los mismas
WO2016125191A3 (en) Processes for the preparation of vortioxetine hydrobromide
IN2013MU00711A (pt)
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
IN2013MU01985A (pt)
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112018069782A2 (pt) composição farmacêutica de dapagliflozina
CL2019000766A1 (es) Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes.
BR112016027819A8 (pt) processo de preparação de derivados de tiazole
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
BR112018016346A2 (pt) processo
BR112017023877A2 (pt) método de produção de um composto à base de mercúrio, o composto à base de mercúrio, os métodos para utilização do composto à base de mercúrio e as utilizações do composto à base de mercúrio
BR112018006444A2 (pt) processo para a preparação de uma composição lipossomal unilamelar e composição lipossomal liofilizada
CL2020000017A1 (es) Composición novedosa de la forma de dosificación oral de la enzalutamida y su método de fabricación.
BR112017012021A2 (pt) um processo para a fabricação de idalopirdina
BR112016028081A2 (pt) Novos compostos como agentes antituberculares
BR112018013184A2 (pt) processo para preparação de um granulado revestido entérico compreendendo dimetilfumarato

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2703 DE 25/10/2022.